Izuralimab Reference: HY-P99679 Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 100ug mIgG1 Ab Reference: AT7001-mIgG1-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Anatumomab mafenatox Reference: HY-P99436 Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness.
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 500ug mIgG1 Ab Reference: AT7001-mIgG1-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Bezlotoxumab Reference: HY-P9929 Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis.
oYo-Link® DM1 Antibody Labeling Kit - Labels 100ug Reference: AT7002-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Transferrin aldifitox Reference: HY-P99549 Transferrin aldifitox (TF-CRM107) is a diphtheria toxin CRM107 conjugate with transferrin. Transferrin aldifitox can be used to research anticancer.
oYo-Link® DM1 Antibody Labeling Kit- Labels 500ug Reference: AT7002-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Foralumab Reference: HY-P99199 Foralumab (NI-0401) is a potent, orally active humanized monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells.
oYo-Link® DM1 Antibody Labeling Kit - Labels 1mg Reference: AT7002-1000 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Elarekibep Reference: HY-P99935 Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma.
oYo-Link® DM1 Antibody Labeling Kit- Labels 100ug mIgG1 Ab Reference: AT7002-mIgG1-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com